Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
London School of Hygiene & Tropical Medicine, London, UK.
Lancet Public Health. 2023 May;8(5):e364-e377. doi: 10.1016/S2468-2667(23)00079-8.
COVID-19 has been shown to differently affect various demographic and clinical population subgroups. We aimed to describe trends in absolute and relative COVID-19-related mortality risks across clinical and demographic population subgroups during successive SARS-CoV-2 pandemic waves.
We did a retrospective cohort study in England using the OpenSAFELY platform with the approval of National Health Service England, covering the first five SARS-CoV-2 pandemic waves (wave one [wild-type] from March 23 to May 30, 2020; wave two [alpha (B.1.1.7)] from Sept 7, 2020, to April 24, 2021; wave three [delta (B.1.617.2)] from May 28 to Dec 14, 2021; wave four [omicron (B.1.1.529)] from Dec 15, 2021, to April 29, 2022; and wave five [omicron] from June 24 to Aug 3, 2022). In each wave, we included people aged 18-110 years who were registered with a general practice on the first day of the wave and who had at least 3 months of continuous general practice registration up to this date. We estimated crude and sex-standardised and age-standardised wave-specific COVID-19-related death rates and relative risks of COVID-19-related death in population subgroups.
18 895 870 adults were included in wave one, 19 014 720 in wave two, 18 932 050 in wave three, 19 097 970 in wave four, and 19 226 475 in wave five. Crude COVID-19-related death rates per 1000 person-years decreased from 4·48 deaths (95% CI 4·41-4·55) in wave one to 2·69 (2·66-2·72) in wave two, 0·64 (0·63-0·66) in wave three, 1·01 (0·99-1·03) in wave four, and 0·67 (0·64-0·71) in wave five. In wave one, the standardised COVID-19-related death rates were highest in people aged 80 years or older, people with chronic kidney disease stage 5 or 4, people receiving dialysis, people with dementia or learning disability, and people who had received a kidney transplant (ranging from 19·85 deaths per 1000 person-years to 44·41 deaths per 1000 person-years, compared with from 0·05 deaths per 1000 person-years to 15·93 deaths per 1000 person-years in other subgroups). In wave two compared with wave one, in a largely unvaccinated population, the decrease in COVID-19-related mortality was evenly distributed across population subgroups. In wave three compared with wave one, larger decreases in COVID-19-related death rates were seen in groups prioritised for primary SARS-CoV-2 vaccination, including people aged 80 years or older and people with neurological disease, learning disability, or severe mental illness (90-91% decrease). Conversely, smaller decreases in COVID-19-related death rates were observed in younger age groups, people who had received organ transplants, and people with chronic kidney disease, haematological malignancies, or immunosuppressive conditions (0-25% decrease). In wave four compared with wave one, the decrease in COVID-19-related death rates was smaller in groups with lower vaccination coverage (including younger age groups) and conditions associated with impaired vaccine response, including people who had received organ transplants and people with immunosuppressive conditions (26-61% decrease).
There was a substantial decrease in absolute COVID-19-related death rates over time in the overall population, but demographic and clinical relative risk profiles persisted and worsened for people with lower vaccination coverage or impaired immune response. Our findings provide an evidence base to inform UK public health policy for protecting these vulnerable population subgroups.
UK Research and Innovation, Wellcome Trust, UK Medical Research Council, National Institute for Health and Care Research, and Health Data Research UK.
COVID-19 已被证明对不同的人口统计学和临床人群亚组有不同的影响。我们旨在描述在连续的 SARS-CoV-2 大流行浪潮中,临床和人口统计学人群亚组中 COVID-19 相关死亡率的绝对和相对风险的变化趋势。
我们在英格兰使用 OpenSAFELY 平台进行了一项回顾性队列研究,该研究得到了英国国民保健服务局的批准,涵盖了 SARS-CoV-2 大流行的前五个浪潮(第一波[野生型],2020 年 3 月 23 日至 5 月 30 日;第二波[阿尔法(B.1.1.7)],2020 年 9 月 7 日至 2021 年 4 月 24 日;第三波[德尔塔(B.1.617.2)],2021 年 5 月 28 日至 12 月 14 日;第四波[奥密克戎(B.1.1.529)],2021 年 12 月 15 日至 2022 年 4 月 29 日;第五波[奥密克戎],2022 年 6 月 24 日至 8 月 3 日)。在每一波中,我们纳入了在波开始的第一天在普通诊所登记且在该日期之前至少有 3 个月连续普通诊所登记的年龄在 18-110 岁的人群。我们估计了人群亚组中 COVID-19 相关死亡率的粗死亡率、性别标准化死亡率和年龄标准化死亡率以及 COVID-19 相关死亡率的相对风险。
在第一波中纳入了 18895870 名成年人,在第二波中纳入了 19014720 名成年人,在第三波中纳入了 18932050 名成年人,在第四波中纳入了 19097970 名成年人,在第五波中纳入了 19226475 名成年人。每 1000 人年的 COVID-19 相关粗死亡率从第一波的 4.48 例(95%CI 4.41-4.55)下降到第二波的 2.69(2.66-2.72),第三波的 0.64(0.63-0.66),第四波的 1.01(0.99-1.03),以及第五波的 0.67(0.64-0.71)。在第一波中,年龄在 80 岁或以上、慢性肾脏病 5 或 4 期、接受透析、痴呆或学习障碍以及接受过肾移植的人群的标准化 COVID-19 相关死亡率最高,范围从每 1000 人年 19.85 例死亡到每 1000 人年 44.41 例死亡,而其他亚组的死亡率从每 1000 人年 0.05 例死亡到每 1000 人年 15.93 例死亡。与第一波相比,在第二波中,在未接种疫苗的人群中,COVID-19 相关死亡率的下降在人群亚组中分布均匀。与第一波相比,在第三波中,优先接种 SARS-CoV-2 疫苗的人群(包括 80 岁或以上的人群和患有神经系统疾病、学习障碍或严重精神疾病的人群)的 COVID-19 相关死亡率下降幅度更大(90-91%)。相反,COVID-19 相关死亡率的下降幅度较小(0-25%)的人群包括年龄较小的人群、接受过器官移植的人群以及患有慢性肾脏病、血液系统恶性肿瘤或免疫抑制状况的人群。与第一波相比,在第四波中,疫苗接种率较低(包括年龄较小的人群)和疫苗反应受损相关的条件(包括接受过器官移植的人群和患有免疫抑制状况的人群)的人群中 COVID-19 相关死亡率的下降幅度较小(26-61%)。
在总体人群中,COVID-19 相关死亡率绝对数随时间呈显著下降趋势,但人口统计学和临床相对风险特征仍然存在,且在疫苗接种率较低或免疫反应受损的人群中恶化。我们的研究结果为英国公共卫生政策提供了循证依据,以保护这些弱势群体。
英国研究与创新署、惠康信托基金会、英国医学研究理事会、国民保健制度研究与创新中心以及英国健康数据研究中心。